First Health Economic Outcomes Research with Sonata Treatment to be Presented
Redwood City, CA – Nov 10, 2016 – Gynesonics, a women’s healthcare company focused on the development of advanced incision-free solutions for the treatment of uterine conditions, today announced that its Sonata® System technology platform for transcervical incision-free treatment of uterine fibroids will be featured in four presentations at the 45th Annual American Association of Gynecologic Laparoscopists (AAGL) Global Congress November 14-18 at the Rosen Hotel at Shingle Creek in Orlando, Florida.
The AAGL is the leading association promoting minimally invasive gynecologic surgery among surgeons worldwide. Its membership extends to more than 110 countries and more than 7,000 members globally.
The presentations will include the first health economic outcomes data based on treatment with the Sonata System, an incision-free, transervical treatment for uterine fibroids that preserves the uterus, noted Gynesonics President and CEO Christopher M. Owens. “This data is critically important to our global reimbursement strategy and to providers and payers, “ Owens said. “We are building upon the impressive clinical outcomes being achieved with Sonata. Providing the associated health economic outcomes research, essential to validating an innovative technology, is one additional piece. As a company, Gynesonics is committed to providing the gynecology community a new incision-free, transcervical, uterus preserving option for the treatment of symptomatic uterine fibroids.”
Topics and presenters include:
Wednesday, 16 November Session: Open Communication 04 – New Instrumentation or Technology, Room: Panzacola G-2
- 12:24pm Intrauterine Sonography Guided Transcervical RF-Ablation of Symptomatic Uterine Fibroids: Results of a New Therapeutic Option in a Single Institution,” Ralf Bends, M.D., Protestant Hospital, Cologne-Weyertal, Germany
- 12:42pm Improvement in Health Utility After Transcervical Radiofrequency Ablation of Uterine with the Sonata System, Elizabeth Brooks, Ph.D., Decision Driver Analytics, Asheville, NC
- 12:49pm Early Results of the SONATA Study: Sonography Guided Transcervical Ablation of Uterine Fibroids, Kelly Roy, M.D., Arizona Gynecology Consultants, Phoenix, Arizona.
Thursday, 17 November Session: Open Communication 19 – New Instrumentation or Technology, Room: Panzacola G-2
- 2:54pm Pregnancy Outcomes Following Hyperthermic Fibroid Ablation, Julia G. Keltz, MD, Montefiore Medical Center, Bronx, NY 2
About Sonata System
The Sonata System, the next generation of Gynesonics’ fibroid treatment platform (the previous generation referred to as VizAblate), uses radiofrequency energy to ablate fibroids under intrauterine sonography guidance. The Sonata System, including the SMART Targeting Guide, enables the operator to target and ablate fibroids. Sonata System’s design provides a straightforward, transcervical access for a uterus preserving, incision-free fibroid treatment. This intrauterine approach is designed to avoid the peritoneal cavity.
Gynesonics is a women’s healthcare company focused on advanced incision-free solutions for treatment of uterine conditions. Gynesonics has developed the Sonata System for the transcervical treatment of symptomatic uterine fibroids under intrauterine sonography guidance. The Sonata System is CE Marked and approved for sale in the European Union. Sonata System is not available for sale in the United States. Gynesonics is a privately held company with headquarters in Redwood City, CA.
CONTACT: Chris Owens Gynesonics President and CEO +1.650.216.3860 www.gynesonics.com